Luminescent reagent for detecting FGF21 and use thereof
Through magnetic microsphere coupling and acridinium ester antibody crosslinking technology, high sensitivity and specific FGF21 detection reagents were prepared, solving the sensitivity and accuracy of FGF21 detection in the prior art, and achieving efficient detection of metabolic disease diagnosis .
Patent Information
- Application Number
- PCT/CN2023/142866
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2023-12-28
- Publication Date
- 2024-12-05
AI Technical Summary
The existing FGF21 detection methods have problems such as insufficient sensitivity, inconvenient operation and limited detection accuracy, especially when FGF21 binds to other proteins, which affects the treatment and diagnosis of metabolic diseases.
Using the improved luminescence reagent preparation method, a high sensitivity and specific FGF21 detection reagent was prepared through magnetic microsphere coupling and acridinium ester antibody cross-linking technology, which reduced the amount of antibody used and improved detection accuracy and cost-effectiveness.
High accuracy, sensitivity and specificity of FGF21 detection is achieved, which reduces detection costs and can effectively destroy the binding of FGF21 to other proteins, improving the accuracy of detection.
Smart Images

Figure PCTCN2023142866-FTAPPB-I100001 
Figure PCTCN2023142866-FTAPPB-I100002 
Figure PCTCN2023142866-FTAPPB-I100003
Abstract
Description
A luminescent reagent for detecting FGF21 and its application Technical Field
[0001] The present invention belongs to the field of biomedicine, and particularly relates to a luminescent reagent for detecting FGF21 and an application thereof. Background Art
[0002] Fibroblast growth factor 21 (FGF21) is an endocrine member of the FGF superfamily. Currently identified FGF proteins belong to a family of signaling molecules that regulate the growth and differentiation of various cell types. FGF proteins are of great significance to human physiology and pathology, specifically in embryogenesis, vascular development and growth, and bone growth. Most members of the FGF family are associated with cellular activities, including mitosis, development, angiogenesis, and cell survival. FGF21 is a biomarker for metabolic diseases such as diabetes, and elevated serum levels have been observed in obese subjects, subjects with non-alcoholic fatty liver disease (NAFLD), and subjects with type 2 diabetes. FGF21 expression in skeletal muscle, kidneys, heart, and blood vessels is approximately 7-10 times higher than in the liver.
[0003] Considering the important role of FGF21 in the treatment and development of metabolic diseases, this field still needs detection methods and detection products with higher accuracy, sensitivity and specificity.
[0004] The currently commonly used ELISA method is inconvenient to operate, has a long incubation time, and lacks sensitivity. However, the chemiluminescence method offers high sensitivity and specificity for detecting FGF21, is convenient and rapid, and can be fully automated. FGF21 has unique characteristics in the blood circulation, such as binding to other proteins and being easily degraded, which poses challenges to accurate detection. Therefore, it is necessary to develop a rapid detection method that can simultaneously disrupt the binding of FGF21 to other proteins, releasing FGF21 and enabling more accurate detection.
[0005] Summary of the Invention
[0006] To provide a highly accurate, sensitive, and specific FGF21 detection method and product, the present invention improves the preparation method of a luminescent reagent. The luminescent reagent prepared by the present invention can accurately detect FGF21 protein, providing a more effective detection method and product for clinical testing. Furthermore, the preparation method of the present invention uses a low amount of antibody, which ensures detection effectiveness while reducing product costs.
[0007] Specifically, the present invention provides the following technical solutions:
[0008] Coupling method of magnetic microspheres
[0009] In a first aspect, the present invention provides a method for coupling microspheres, comprising the following steps:
[0010] 1) Microsphere activation: The microspheres were activated using EDC and sulfo-NHS prepared in 0.1 M MES pH 5.0.
[0011] 2) Cross-linking the microspheres with antibodies: washing the activated microspheres obtained in step 1), and cross-linking with antibodies in a cross-linking buffer;
[0012] 3) Microsphere washing: Add 1x TBST and shake at 2000 rpm / min for 1 minute, then remove the supernatant;
[0013] 4) Blocking after cleaning: Use ethylenediamine and fatty alcohol polyoxyethylene ether (AEO) for blocking.
[0014] Preferably, the microspheres include magnetic microspheres, latex microspheres, nano-microspheres, and protein microspheres.
[0015] Preferably, the microspheres are magnetic microspheres.
[0016] Preferably, the microspheres are magnetic microspheres with COOH groups covered on the surface.
[0017] Preferably, the microspheres are washed microspheres, and the washing method is well known in the art; for example, after resuspending with a buffer, placing on an oscillator and mixing and shaking at 2000 rpm / min, with 1 minute as one wash; preferably, the buffer is 1 ml 0.1 M MES pH 5.0.
[0018] Preferably, the amount of EDC used is 5-200 μg EDC / mg magnetic beads; preferably, the amount of EDC used is 20-100 μg EDC per mg magnetic beads. Specifically, the 20-100 includes 20, 30, 40, 50, 60, 70, 80, 90, 100, etc.
[0019] More preferably, the amount of EDC used is 20 μg EDC / mg magnetic beads.
[0020] Preferably, the molar ratio of EDC to sulfoNHS in step 1) is 1:0.5-2;
[0021] More preferably, the molar ratio of EDC to sulfoNHS in step 1) includes a molar ratio of EDC to sulfoNHS of 1:0.5, 1:1, 1:2, etc.
[0022] More preferably, the molar ratio of EDC to sulfoNHS in step 1) is 1:1-1:2.
[0023] Most preferably, the molar ratio of EDC to sulfoNHS in step 1) is 1:1.
[0024] Preferably, the pH value of the cross-linking solution in step 2) is in the range of 7.4-9.5, specifically including 7.4, 7.5, 8, 8.5, 9, 9.5, etc.
[0025] Preferably, the cross-linking solution in step 2) comprises PBS pH 7.4 and NaHCO 3 pH 9.5.
[0026] More preferably, the cross-linking liquid in step 2) is NaHCO 3 pH 9.5.
[0027] Preferably, the antibody concentration in step 2) is 0.05-0.5 mg / ml. Specifically, it includes 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, etc. More preferably, the antibody concentration in step 2) is 0.2-0.4 mg / ml.
[0028] More preferably, the antibody concentration in step 2) is 0.2 mg / ml.
[0029] Preferably, the cleaning step in step 3) is performed once or multiple times, more preferably, a total of 5 times;
[0030] Preferably, the final concentration of the ethylenediamine and the fatty alcohol polyoxyethylene ether (AEO) is independently 1%.
[0031] Preferably, the blocking step is to remove the supernatant and add ethylenediamine and fatty alcohol polyoxyethylene ether (AEO) to a final concentration of 1%, place on an oscillator and mix and shake at 2000 rpm / min for 2 hours, and perform the blocking condition at room temperature.
[0032] Preferably, the antibody includes an antibody that specifically binds to any protein, the structure of which is well known in the art.
[0033] More preferably, the antibody of the present invention is an antibody targeting FGF21 protein; it has the ability to specifically bind to FGF21.
[0034] On the other hand, the present invention provides immunomagnetic microspheres (or simply "magnetic beads" or "magnetic microspheres") prepared by the above coupling method and their use in detecting FGF21. Specifically, the immunomagnetic microspheres are magnetic microspheres coupled with antibodies.
[0035] On the other hand, the present invention provides a kit comprising the above-mentioned immunomagnetic microspheres and its use in detecting FGF21.
[0036] Acridinium ester antibody cross-linking method
[0037] On the other hand, the present invention also provides a method for cross-linking an acridinium ester and an antibody, the method comprising the following steps:
[0038] 1) Cross-linking: Acridinium ester and antibody were added to a cross-linking solution (NaHCO3, pH 9.5) with a molar ratio of acridinium ester to antibody of 20:1.
[0039] 2) Blocking: Blocking was performed using a blocking solution comprising 9% glycine, 1% bsa, 50 mM tris, 300 mM NaCL, pH 8.0.
[0040] Preferably, the acridinium ester includes but is not limited to Me-DMAE-NHS, NSP-DMAE-NHS, ME-AE-NHS, DMAE-NHS, NSP-DMAE-NHS, and NSP-SA-NHS. Specifically, in the specific examples of the present invention, NSP-DMAE-NHS is used as an example to demonstrate that the method of the present invention is applicable to various acridinium esters.
[0041] Preferably, the antibody includes an antibody that specifically binds to any protein, the structure of which is well known in the art.
[0042] More preferably, the antibody of the present invention is an antibody targeting FGF21 protein; it has the ability to specifically bind to FGF21.
[0043] On the other hand, the present invention provides a cross-linked product of acridinium and antibody (prepared product) prepared by the aforementioned cross-linking method of acridinium ester and antibody and its use in detecting FGF21.
[0044] On the other hand, the present invention provides a kit comprising the cross-linked product of acridine and antibody as described above and its use in detecting FGF21.
[0045] Preparation method of luminescent reagent
[0046] In another aspect, the present invention provides a preparation method for preparing a luminescent reagent for detecting FGF21, the method comprising:
[0047] Step 1, the coupling method of the aforementioned magnetic microspheres, and;
[0048] Step 2: cross-linking of acridinium ester and antibody.
[0049] Preferably, the antibodies in the above steps 1 and 2 include antibodies that specifically bind to any protein, and the structures of which are well known in the art; more preferably, the antibodies specifically bind to FGF21.
[0050] More specifically, the preparation method of the FGF21 detection luminescent reagent comprises the following steps:
[0051] Step 1, coupling of magnetic microspheres:
[0052] 1) Microsphere activation: Magnetic microspheres were activated using EDC and sulfo-NHS prepared in 0.1 M MES pH 5.0.
[0053] 2) Cross-linking the microspheres with antibodies: washing the activated microspheres obtained in step 1), and cross-linking with antibodies in a cross-linking buffer;
[0054] 3) Microsphere washing: Add 1x TBST and shake at 2000 rpm / min for 1 minute, then remove the supernatant. Wash five times in total.
[0055] 4) Blocking after cleaning: Use ethylenediamine and fatty alcohol polyoxyethylene ether (AEO) for blocking.
[0056] Step 2: Cross-linking of Acridinium Ester and Antibody
[0057] 1) Cross-linking: Acridinium ester and antibody were added to a cross-linking solution. The cross-linking solution was prepared by adding 300 mM NaCl to 50 mM tris, and the pH was adjusted to 9.0. The molar ratio of acridinium ester to antibody in the solution was 20:1.
[0058] 2) Blocking: Blocking was performed using a blocking solution comprising 9% glycine, 1% bsa, 50 mM tris, 300 mM NaCL, pH 8.0.
[0059] On the other hand, the present invention provides a luminescent reagent prepared by the above preparation method and its application in detecting FGF21.
[0060] On the other hand, the present invention provides a kit comprising the luminescent reagent prepared by the above preparation method and its use in detecting FGF21.
[0061] Preferably, the kit may also include any one or more of the following products: a standard sample (quality control sample) of the antigen to be detected, a storage solution for the immunomagnetic microspheres, a sample collection and processing reagent reaction container (reaction well), a magnetic separation device, and a washing device.
[0062] How to use
[0063] In another aspect, the present invention provides a method for using an FGF21 luminescent reagent, comprising the following steps:
[0064] 1) adding the magnetic beads prepared by the coupling method of the magnetic microspheres in step 1 above, mixing with the sample, and incubating; the magnetic microspheres are diluted in the storage solution of the present invention before use;
[0065] 2) Cleaning;
[0066] 3) adding the antibody cross-linked by the acridinium ester and antibody cross-linking method in step 2 above, mixing, and incubating; the cross-linked product is used in the storage solution of the present invention;
[0067] 4) Remove the magnetic beads, add the luminescent pre-excitation solution, shake to mix, then add 100 μl of excitation solution and immediately read the luminescent signal value.
[0068] Preferably, the incubation step is 10 minutes at 37 degrees.
[0069] Preferably, the washing step is performed one or more times by removing the supernatant, adding 500 μl of washing solution, and shaking to mix; preferably, washing is performed three times;
[0070] Preferably, the dilution concentration of the magnetic microspheres is 10-100 mg / L, most preferably, 50 mg / L;
[0071] Preferably, the dilution concentration of the cross-linker is 0.1-0.5 mg / L, most preferably, 0.2 mg / L.
[0072] Save solution
[0073] On the other hand, the present invention provides a storage solution for a luminescent reagent, which includes a buffer, a reducing agent and a surfactant, wherein the buffer includes any one or more of PBS pH 7.4, MOPS pH 6.4 or MES pH 5.0; the reducing agent includes any one or more of DTT, beta-ME or GSSG; and the surfactant includes any one or more of tween20, tween80, tritonX-100 or SDS / NP40.
[0074] In another aspect, the present invention provides use of the above preservation solution in preserving a luminescent reagent, wherein the luminescent reagent is a coupling product of an acridinium ester, an antibody, and microspheres.
[0075] Preferably, the acridinium ester in the luminescent reagent includes luminescent substances including Me-DMAE-NHS, NSP-DMAE-NHS, ME-AE-NHS, DMAE-NHS, NSP-DMAE-NHS, and NSP-SA-NHS.
[0076] Preferably, the antibody includes an antibody that specifically binds to any protein, the structure of which is well known in the art.
[0077] Preferably, the microspheres include magnetic microspheres (magnetic beads), latex microspheres, nanospheres, and protein microspheres (BSA-NS).
[0078] Preferably, the microspheres are magnetic microspheres.
[0079] Preferably, the microspheres are magnetic microspheres with COOH groups covered on the surface.
[0080] As described in the present invention, "magnetic microspheres" can also be called magnetic polymer microspheres, magnetic microspheres, magnetic beads, and magnetic polymer microspheres; according to their internal structure, they are classified into core-shell type, reverse core-shell type, sandwich type, and dispersion type; the magnetic material used can be pure iron powder, carbonyl iron, magnetic ore, orthoferrite, iron-cobalt alloy, etc.; its skeleton material can be: polymer carrier skeleton material such as amino acid polymers such as proteins, peptides, enzymes, etc.; polysaccharides such as gum arabic, starch, dextran, agarose, etc., and other polymers such as polypropylene, polyethylene, silicone, etc.
[0081] In the present invention, "cross-linking" and "coupling" have the same meaning and can be replaced with each other. DETAILED DESCRIPTION
[0082] The present invention will be further described below with reference to the following embodiments. The following description is merely a preferred embodiment of the present invention and does not limit the present invention in any other form. Any person skilled in the art may utilize the above disclosed technical content to make equivalent embodiments with equivalent variations. Any simple modification or equivalent variation of the following embodiments made in accordance with the technical essence of the present invention without departing from the content of the present invention shall fall within the scope of protection of the present invention.
[0083] Comparative Example 1: Preparation of FGF21 Luminescent Reagent
[0084] Step 1: Cross-linking of magnetic microspheres
[0085] 1) Microsphere activation:
[0086] 10 mg of COOH-coated magnetic microspheres (1-3 μm in diameter) were magnetically separated for 1 minute. After 1 minute of magnetic separation, the supernatant was discarded and the microspheres were resuspended in 1 ml of 0.1 M MES pH 5.0. The microspheres were then shaken on a shaker at 2000 rpm for 1 minute each. After three washes, the microspheres were resuspended in 1 ml of 0.1 M MES pH 5.0. A two-step activation method was used: 20 μl of a 10 mg / mL EDC solution was added, followed by 28 μl of a 10 mg / mL sulfo-NHS solution.
[0087] The EDC solution and sulfo-NHS solution were prepared using 0.1 M MES pH 5.0 and used immediately.
[0088] The amount of EDC used was 20 μg EDC / mg magnetic beads (i.e., 20 μg EDC was added per mg of magnetic beads). The molar ratio of EDC to sulfoNHS was 1:1.
[0089] 2) Cross-linking of microspheres with FGF21 antibodies:
[0090] After washing and activation, the microspheres were cross-linked with FGF21-specific antibodies (purchased from Hong Kong Uni-Diagnostics Co., Ltd.) in a cross-linking solution of NaHCO3 (pH 9.5) at an antibody concentration of 0.2 mg / ml and a microsphere concentration of 10 mg / ml. The washing method was the same as in step 1).
[0091] 3) Microsphere Washing: Add 1x TBST (0.1M Tris, 150mM NaCl, 0.05% Tween 20 (v / v), pH 7.4) and shake on a shaker at 2000 rpm / min for 1 minute per wash. After each wash, adsorb onto a magnetic plate and discard the supernatant. Wash five times in total.
[0092] 4) Blocking after washing: After removing the supernatant, add ethylenediamine and fatty alcohol polyoxyethylene ether (AEO) to a final concentration of 1%. Place on an oscillator and shake at 2000 rpm / min for 2 hours. This is done at room temperature under blocking conditions.
[0093] 5) After blocking, the cross-linked FGF21-specific antibody magnetic beads were diluted into the FGF21 luminescent reagent storage solution described in Example 2 at a concentration of 50 mg / L.
[0094] Step 2: Acridinium ester antibody cross-linking
[0095] 1) Cross-linking: Add acridinium ester (NSP-DMAE-NHS) and FGF21-specific antibody to a cross-linking solution at a concentration of 1 mg / ml. The cross-linking solution is NaHCO3 (pH 9.5), and the molar ratio of acridinium ester to antibody is 20:1. Mix and shake on a shaker at 2000 rpm / min and incubate at room temperature for 1 hour.
[0096] 2) Blocking: After cross-linking, add 1 ml of blocking solution (9% glycine, 1% BSA, 50 mM Tris, 300 mM NaCl, pH 8.0) and shake on a shaker at 2000 rpm for 1 hour at room temperature.
[0097] After blocking, the FGF21-specific antibody conjugated with acridinium ester was diluted into the FGF21 luminescent reagent storage solution described in Example 2 at a concentration of 200 ng / ml (0.2 mg / l) to serve as the detection antibody.
[0098] Comparative Example 2
[0099] The only difference from Comparative Example 1 is that the amount of EDC used is 5 μg EDC / mg magnetic beads.
[0100] Comparative Example 3
[0101] The only difference from Comparative Example 1 is that the amount of EDC used is 40 μg EDC / mg magnetic beads.
[0102] Comparative Example 4
[0103] The only difference from Comparative Example 1 is that the amount of EDC used is 100 μg EDC / mg magnetic beads.
[0104] Comparative Example 5
[0105] The only difference from Comparative Example 1 is that the amount of EDC used is 200 μg EDC / mg magnetic beads.
[0106] Comparative Example 6
[0107] The only difference from Comparative Example 1 is that the molar ratio of EDC to sulfoNHS is 1:2.
[0108] Comparative Example 7
[0109] The only difference from Comparative Example 1 is that the molar ratio of EDC to sulfoNHS is 2:1.
[0110] Comparative Example 8
[0111] The only difference from Comparative Example 1 is that the buffer used for cross-linking the microsphere antibody is mops pH 6.4.
[0112] Comparative Example 9
[0113] The only difference from Comparative Example 1 is that the buffer used for cross-linking the microsphere antibody is PBS pH 7.4.
[0114] Comparative Example 10
[0115] The only difference from Comparative Example 1 is that the antibody concentration is 0.05 mg / ml.
[0116] Comparative Example 11
[0117] The only difference from Comparative Example 1 is that the antibody concentration is 0.1 mg / ml.
[0118] Comparative Example 12
[0119] The only difference from Comparative Example 1 is that the antibody concentration is 0.3 mg / ml.
[0120] Comparative Example 13
[0121] The only difference from Comparative Example 1 is that the antibody concentration is 0.4 mg / ml.
[0122] Comparative Example 14
[0123] The only difference from Comparative Example 1 is that the cleaning was allowed to stand for 3 minutes without shaking.
[0124] Comparative Example 15
[0125] The only difference from Comparative Example 1 is that Tris is used alone as the blocking solution.
[0126] Comparative Example 16
[0127] The only difference from Comparative Example 1 is that 1% BSA is added to the blocking solution Tirs.
[0128] Comparative Example 17
[0129] The only difference from Comparative Example 1 is that the sealing step is left to stand without shaking.
[0130] Table 1. Comparative Examples Summary
[0131] Example 1: Optimization of FGF21 chemiluminescence kit
[0132] The FGF21 chemiluminescence kits prepared in Comparative Examples 1 to 15 were assayed on the IncreCare Shine i1910, a fully automated biochemical analyzer. Test samples included a blank sample and FGF21 calibrators at varying concentrations: 30 pg / ml, 60 pg / ml, 120 pg / ml, 240 pg / ml, 480 pg / ml, 960 pg / ml, and 1920 pg / ml.
[0133] The computer test procedure is:
[0134] 1. Take 50 μl of sample and 50 μl of magnetic beads cross-linked with FGF21-specific antibody (magnetic beads prepared by cross-linking magnetic microspheres in step 1 above), add them to the luminescence reaction tube, mix well and incubate at 37 degrees for 10 minutes.
[0135] 2. After incubation, wash the beads according to the instrument's designated washing procedures: First, perform magnetic separation, remove the supernatant, add 500 μl of washing solution, and vortex to mix. Repeat these steps three times. Perform magnetic separation again, and remove the supernatant.
[0136] 3. Add 100 μl of acridinium ester-coupled FGF21-specific antibody detection antibody (the antibody obtained by cross-linking acridinium ester antibodies in step 2 above) to the light-emitting tube, mix with the magnetic beads, incubate for 10 minutes, and wash three times by the instrument fixed cleaning step as described in the previous step.
[0137] 4. After washing, perform magnetic separation, remove the supernatant and retain the magnetic beads, add 100 μl of luminescent pre-excitation solution (purchased from Nanjing Renmai Biotechnology Co., Ltd.), shake and mix, then add 100 μl of excitation solution (purchased from Nanjing Renmai Biotechnology Co., Ltd.), and immediately read the luminescent signal value.
[0138] 1) Optimization of EDC usage
[0139] The signal values obtained by detecting FGF21 calibrators of different concentrations using microspheres prepared with different EDC concentrations are summarized in Table 2 (Comparative Examples 1 to 5).
[0140] Table 2. Comparison of detection reagents prepared using different EDC concentrations
[0141] As shown in Table 2, the present invention uses microspheres prepared with different EDC concentrations to test different concentrations of FGF21 calibrators. Under low EDC concentration conditions (Comparative Example 2, 5 μg EDC / mg magnetic beads), the luminescence value of the calibration curve is low, and the reagent sensitivity is low. As the EDC concentration increases, the reagent signal also increases, and the sensitivity improves, but at the same time, the reagent background (0 pg / ml) signal also increases, the signal-to-noise ratio decreases, and it will lead to a decrease in reagent specificity. Therefore, the present invention prefers Comparative Examples 1, 3, and 4; Comparative Example 1 is further preferred.
[0142] 2) Optimization of the molar ratio of EDC and sulfoNHS
[0143] The signal values obtained by detecting different concentrations of FGF21 calibrators using microspheres prepared with different molar ratios of EDC and sulfoNHS are summarized in Table 3 (Comparative Example 1, Comparative Example 6, Comparative Example 7).
[0144] Table 3. Comparison of detection reagents prepared with different molar ratios of EDC and sulfoNHS
[0145] As shown in Table 3, the present invention tested FGF21 calibrators of varying concentrations using microspheres prepared using varying EDC / sulfo NHS molar ratios. At EDC / sulfo NHS molar ratios of 1:1 and 1:2, the calibrator showed high reactivity and low reagent blank background. At a 2:1 EDC / sulfo NHS molar ratio, while the calibrator signal was high, the reagent blank background was high, leading to decreased reagent specificity. Therefore, the present invention prefers Comparative Examples 1 and 6; Comparative Example 1 is further preferred.
[0146] 3) Optimization of cross-linking solution
[0147] Microspheres prepared under different cross-linking solution conditions were tested for signal values obtained from different concentrations of FGF21 calibrators (Comparative Examples 1, 8, and 9).
[0148] Table 4. Comparison of detection reagents prepared with different cross-linking solutions
[0149] As shown in Table 4, the present invention tested FGF21 calibrators of varying concentrations using microspheres prepared using different crosslinking solutions. Comparative Example 8 represents a conventional protocol in the industry. For FGF21, the signal value obtained from the calibrator tested in Comparative Example 9 increased by approximately 50% compared to the conventional protocol, and the signal value obtained in Comparative Example 1 nearly doubled compared to the conventional protocol. Meanwhile, the blank background remained unchanged, demonstrating that the reagent sensitivity was significantly improved under the conditions of Comparative Examples 9 and 1 without compromising specificity. Therefore, the present invention prefers Comparative Examples 1 and 9; Comparative Example 1 is further preferred.
[0150] 4) Optimization of FGF21-specific antibody concentration
[0151] Microspheres prepared by coupling FGF21-specific antibodies at different concentrations were used to detect the signal values obtained from FGF21 calibrators at different concentrations (Comparative Examples 1, 10 to 13):
[0152] Table 5. Comparison of detection reagents prepared by coupling FGF21-specific antibodies at different concentrations
[0153] As shown in Table 5, the present invention used microspheres prepared with varying concentrations of FGF21-specific antibodies to test FGF21 calibrators at varying concentrations. As the antibody concentration increased from 0.05 mg / ml to 0.1 mg / ml, and then to 0.2 mg / ml, the calibrator signal significantly increased. However, as the antibody concentration continued to increase, the signal increase was less pronounced, considering reagent costs. Comparative Examples 1, 12, and 13 are preferred, and Comparative Example 1 is further preferred.
[0154] 4) Optimization of cleaning and sealing processes
[0155] FGF21 microspheres prepared with different cleaning and blocking processes were tested for signal values obtained from different concentrations of FGF21 calibrators (Comparative Examples 1, 10 to 13):
[0156] Table 6. Comparison of detection reagents prepared using different cleaning and blocking processes
[0157] As shown in Table 6, the present invention optimizes the cleaning and blocking process for preparing FGF21 microspheres. Compared with traditional Tris or Tirs+BSA blocking processes, the addition of ethylenediamine+AEO and sufficient oscillation during the cleaning and blocking process significantly reduced the microsphere blank signal from 4864 or 3347 to 336, a reduction of 10 times. This can greatly improve the signal-to-noise ratio of the reagent, thereby improving the reagent sensitivity and specificity.
[0158] 5) CV value detection of FGF21 chemiluminescence kit
[0159] The FGF21 chemiluminescent reagent prepared in each comparative example was used to detect the 120 pg / ml FGF21 calibrator according to the above on-machine test procedure. The test was repeated 20 times, and the CV value was calculated as follows.
[0160] CV=SD / M×100%
[0161] Where:
[0162] CV—Coefficient of variation
[0163] SD—standard deviation of 10 measurements
[0164] M—the average value of 10 measurement results
[0165] The cv values are summarized in Table 7. According to the data, the luminescent reagent prepared by the luminescent reagent preparation method provided by the present invention has the best cv value and can accurately and stably detect FGF21 protein.
[0166] Table 7. CV value statistics
[0167] Example 2: Storage solution of FGF21 luminescent reagent
[0168] A preservation solution was prepared, comprising a buffer, a reducing agent, and a surfactant, wherein the buffer was PBS pH 7.4, 50 mM MoPS pH 6.4, or 50 mM MES pH 5.0; the reducing agent was 5 mM DTT, 5 mM beta-ME, or 5 mM GSSG; and the surfactant was 0.1% tween 20, 0.1% tween 80, 0.1% triton X-100, 0.1% SDS, or 0.1% NP40.
[0169] Table 8. Preservative solutions tested by the present invention and their stability at 37°C
[0170] Take the above preservation solution to prepare FGF21 luminescent reagent, and according to the detection method described in Example 1, detect the signal value of FGF21 calibrator of different concentrations. Then the luminescent reagent is stored at 37 degrees for accelerated destruction test. After the 3rd, 7th and 14th days of preservation (time length), the signal value of each level of FGF21 calibrator is detected and compared with the initial signal value to obtain the recovery rate, and the average recovery rate is calculated (Table 8). According to the comparison of the detection, it can be seen that the stability of preservation solution 2, preservation solution 5, preservation solution 7, preservation solution 9, preservation solution 12, and preservation solution 13 is good, and it is further preferred to preserve solution 12, and the stability of preservation solution 13 is the best. Finally, preservation solution 12 is selected as the FGF21 luminescent reagent preservation solution.
Claims
1. A method for coupling microspheres, the method comprising the following steps: 1) Microsphere activation: Take the microspheres and activate them using EDC and sulfo-NHS, wherein the EDC and sulfo-NHS are prepared using 0.1 M MES pH 5.0; 2) Cross-linking the microspheres with antibodies: washing the activated microspheres obtained in step 1), and cross-linking the microspheres with antibodies during a cross-linking night; 3) Microsphere washing: Add 1x TBST and shake at 2000 rpm / min, then separate and discard the supernatant; 4) Sealing after cleaning: Use ethylenediamine and fatty alcohol polyoxyethylene ether for sealing; Preferably, the microspheres include magnetic microspheres, latex microspheres, nano-microspheres, and protein microspheres; Preferably, the microspheres are magnetic microspheres; Preferably, the microspheres are magnetic microspheres with COOH covered on the surface; Preferably, the microspheres are washed microspheres; Preferably, the washing method is to resuspend with a buffer, place on an oscillator and mix and shake at 2000 rpm / min; preferably, the buffer is 1 ml 0.1 M MES PH5.0; Preferably, the amount of EDC used is 5-200 μg EDC / mg magnetic beads, specifically, the amount of EDC used is 20-100 μg EDC per mg magnetic beads; More preferably, the EDC usage is 20 μg EDC / mg magnetic beads; Preferably, in step 1), the molar ratio of EDC to sulfoNHS is 1:0.5-2, specifically, the molar ratio of EDC to sulfoNHS is 1:0.5, 1:1, 1:2, etc.; More preferably, in step 1), the molar ratio of EDC to sulfoNHS is 1:1-1:2; Most preferably, the molar ratio of EDC to sulfoNHS in step 1) is 1:1; Preferably, the pH value of the cross-linking solution in step 2) is in the range of 7.4-9.5; specifically including 7.4, 7.5, 8, 8.5, 9, 9.5; Preferably, the cross-linking solution in step 2) comprises PBS pH 7.4 and NaHCO3 pH 9.5; More preferably, the cross-linking liquid in step 2) is NaHCO3 pH 9.5; Preferably, the antibody concentration in step 2) is 0.05-0.5 mg / ml; the antibody concentration in step 2) is 0.2-0.4 mg / ml; More preferably, the antibody concentration in step 2) is 0.2 mg / ml; Preferably, the final concentration of the ethylenediamine and the fatty alcohol polyoxyethylene ether is independently 1%; Preferably, the cleaning step in step 3) is performed once or multiple times, more preferably, a total of 5 times; Preferably, the blocking step in step 4) is to remove the supernatant and add ethylenediamine and fatty alcohol polyoxyethylene ether to make the final concentration of both 1%, place on an oscillator and mix and shake at 2000 rpm / min, and perform the blocking condition at room temperature; Preferably, the shaking is performed for 2 hours; Preferably, the antibody comprises an antibody that specifically binds to any protein; More preferably, the antibody is an antibody targeting FGF21 protein.
2. The immunomagnetic microspheres prepared by the coupling method according to claim 1 or their use in detecting FGF21.
3. A kit comprising the immunomagnetic microspheres prepared by the coupling method according to claim 3 or use thereof in detecting FGF21.
4. A method for cross-linking an acridinium ester and an antibody, the method comprising the following steps: 1) Cross-linking: Add acridinium ester and antibody to a cross-linking solution, wherein the cross-linking solution is NaHCO3 pH 9.5, and the molar ratio of acridinium ester to antibody in the solution is 20:1; 2) Blocking: Blocking with a blocking solution, which is 9% glycine, 1% bsa, 50 mM tris, 300 mM NaCL, pH 8.0; Preferably, the acridinium ester includes Me-DMAE-NHS, NSP-DMAE-NHS, ME-AE-NHS, DMAE-NHS, NSP-DMAE-NHS, NSP-SA-NHS; Preferably, the acridinium ester is NSP-DMAE-NHS; Preferably, the antibody comprises an antibody that specifically binds to any protein; More preferably, the antibody is an antibody targeting FGF21 protein.
5. The cross-linked product of acridinium and antibody prepared by the cross-linking method of acridinium ester and antibody according to claim 4, or its use in detecting FGF21.
6. A kit comprising the cross-linked product of acridine and an antibody according to claim 5 or use thereof in detecting FGF21.
7. A storage solution for a luminescent reagent or its use in storing a luminescent reagent, wherein the storage solution comprises a buffer, a reducing agent and a surfactant, wherein the buffer comprises any one or more of pbs pH 7.4, 50mM mops pH 6.4 or 50mM mes pH 5.0; the reducing agent comprises any one or more of DTT, beta-ME or GSSG; the surfactant comprises any one or more of tween20, tween80, tritonX-100 or SDS / NP40; Preferably, the buffer is MOPS pH 6.4; Preferably, the reducing agent is Beta ME; Preferably, the surfactant is Tween 20 or Triton X 100; Preferably, the reducing agent is 5 mM Beta ME; Preferably, the surfactant is 0.1% tween20 or 0.1% tritonX-100 of xx; Preferably, the luminescent reagent comprises a coupling product of microspheres and antibodies; Preferably, the luminescent reagent comprises a cross-linked product of an acridinium ester and an antibody; Preferably, the acridinium ester includes Me-DMAE-NHS, NSP-DMAE-NHS, ME-AE-NHS, DMAE-NHS, NSP-DMAE-NHS, NSP-SA-NHS; Most preferably, the acridinium ester is NSP-DMAE-NHS; Preferably, the antibody comprises an antibody that specifically binds to any protein; Preferably, the microspheres include magnetic microspheres, latex microspheres, nano-microspheres, and protein microspheres; Preferably, the microspheres are magnetic microspheres; Preferably, the microspheres are magnetic microspheres with COOH covered on the surface; Preferably, the storage concentration of the coupling product of the microspheres and antibodies is 10-100 mg / L, most preferably, 50 mg / L; Preferably, the cross-linked product of the acridinium ester and the antibody is stored at a concentration of 0.1-0.5 mg / L, most preferably, 0.2 mg / L; Preferably, the luminescent reagent is a product prepared by the method of claim 1 and / or a product prepared by the method of claim 7; Preferably, the storage concentration of the product prepared by the method of claim 1 is 10-100 mg / L, most preferably, 50 mg / L; Preferably, the storage concentration of the product prepared by the method of claim 7 is 0.1-0.5 mg / L, most preferably, 0.2 mg / L.
8. A preparation method or a preparation product of the preparation method or use of the preparation product in detecting FGF21 protein, the method comprising the following steps: Step 1, a coupling method of the magnetic microspheres according to claim 1, and; Step 2, the cross-linking method of the acridinium ester and the antibody according to claim 4.
9. A kit comprising the product prepared according to claim 8 or its use in detecting FGF21; Preferably, the kit may also include any one or more of the following products: a standard of the antigen to be detected, a storage solution for the immunomagnetic microspheres, sample collection and processing reagents, a reaction container, a magnetic separation device, and a washing device.
10. A method for using the product prepared according to claim 9; Preferably, the method of use comprises the following steps: 1) adding the immunomagnetic microspheres prepared by the coupling method of the magnetic microspheres of claim 1 and mixing with the sample, and incubating; the magnetic microspheres are diluted and used in the storage solution of claim 7; 2) Cleaning; 3) adding the cross-linked product obtained by the cross-linking method of the acridinium ester and the antibody according to claim 4, mixing and incubating; the cross-linked product is used in the storage solution according to claim 7; 4) Remove the magnetic beads, add the luminescent pre-excitation solution, shake and mix, then add 100 μl of the excitation solution, and immediately read the luminescent signal value; Preferably, the incubation step is 37 degrees for 10 minutes; Preferably, the washing step is performed once or multiple times by removing the supernatant, adding 500 μl of washing solution, and shaking to mix; preferably, washing is performed three times; Preferably, the dilution concentration of the magnetic microspheres is 10-100 mg / L, most preferably, 50 mg / L; Preferably, the dilution concentration of the cross-linker is 0.1-0.5 mg / L, most preferably, 0.2 mg / L.
Citation Information
Patent Citations
Goldmag particle-based acridinium ester chemiluminescence immunological detection method of HE4
CN104897901A
Method for marking protein by carboxyl microsphere
CN104897904A
Cup type time-resolved fluorescence BNP analysis method and reagent kit based on microspheres
CN105891507A
Carbohydrate antigen CA19-9 assay kit and detection method using the same
CN107389946A
Time-resolved fluorescent immunochromatographic test strip for quantitatively detecting CA153 in blood and preparation method
CN108535485A
Cited By
Capture microsphere, preparation method thereof and high-purity exosome enrichment method
CN119985966A
